eFfector Therapeutics provides clinical data update for Zotatifin

eFFECTOR Therapeutics provided an update on its ongoing clinical development programs for both zotatifin, in Phase 2 expansion cohorts for the treatment of estrogen receptor positive breast cancer and KRAS non-small cell lung cancer as well as Phase 1 development for SARS-CoV-2 , and tomivosertib, in a Phase 2b trial for the treatment of non-small cell lung cancer NSCLC in combination with pembrolizumab, an established anti-immune checkpoint inhibitor used to treat various types of cancer. "We are making steady headway across all our clinical programs and look forward to a number of key data milestones in 2023 for both the zotatifin and tomivosertib programs," remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. "With zotatifin, we continue to see activity across both ER+ BC expansion cohorts, and the drug continues to be generally well-tolerated. The safety results to date have led us to believe that we may be able to increase the dose of zotatifin, which may achieve greater anti-tumor activity. Therefore, we have resumed dose escalation and plan to wait for dose escalation data as well as data from the ongoing ECBF+A cohort before pursuing additional expansion cohorts. We have also completed enrollment in the third and final cohort in our Phase 1b st"Overall, we are pleased with the progress we are making in our clinical programs, and we continue to act thoughtfully and deliberately to direct our attention and resources to where we believe clinical safety and efficacy can most quickly and effectively be demonstrated for both therapeutic candidates," remarked Michael Byrnes, chief financial officer of eFFECTOR. "Concentrating our efforts selectively also allows us to manage our existing cash resources efficiently, which we believe will now carry us into the first quarter of 2024."Phase 1b study with zotatifin in COVID-19 and providing top-line data from this trial in the first half of 2023."